Lipoprotein [a] is cleared from the plasma primarily by the liver in a process mediated by apolipoprotein [a]

Journal of Lipid Research

Volumn 46, Issue 12, 2005, Pages 2681-2691

  Cain, William J ^a   Millar, John S ^b   Himebauch, Adam S ^a,c   Tietge, Uwe J F ^b,d   Maugeais, Cyrille ^b,e   Usher, David ^a   Rader, Daniel J ^b  

^a UNIVERSITY OF DELAWARE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^e F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Apolipoprotein E; Asialoglycoprotein receptor; Kidney; Kinetics; LDL receptor; Tissue distribution

Indexed keywords

APOLIPOPROTEIN A; ASIALOFETUIN; ASIALOGLYCOPROTEIN RECEPTOR; LIGAND; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN RECEPTOR; PROTEIN INHIBITOR;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; KIDNEY; LIPOPROTEIN BLOOD LEVEL; LIVER; MOUSE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; PROTEIN FUNCTION; WILD TYPE;

ALPHA-FETOPROTEINS; ANIMALS; APOLIPOPROTEINS A; APOLIPOPROTEINS E; ASIALOGLYCOPROTEINS; CHOLESTEROL, LDL; LIPOPROTEIN(A); LIVER; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, LDL;

EID: 30844470427     PISSN: 00222275     EISSN: 15397262     Source Type: Journal    
DOI: 10.1194/jlr.M500249-JLR200     Document Type: Article

References (57)

1. Scanu, A. M. 2001. The role of lipoprotein(a) in the pathogenesis of atherosclerotic cardiovascular disease and its utility as predictor of coronary heart disease events. Curr. Cardiol. Rep. 3: 385-390.
2. Hobbs, H. H., and A. L. White. 1999. Lipoprotein(a): intrigues and insights. Curr. Opin. Lipidol. 10: 225-236.
3. Rader, D. J., W. Cain, K. Ikewaki, G. Talley, L. A. Zech, D. Usher, and H. B. Brewer, Jr. 1994. The inverse association of plasma lipoprotein( a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate. J. Clin. Invest. 93: 2758-2763.
4. Rader, D. J., W. Cain, L. A. Zech, D. Usher, and H. B. Brewer, Jr. 1993. Variation in lipoprotein(a) concentrations among individuals with the same apolipoprotein (a) isoform is determined by the rate of lipoprotein(a) production. J. Clin. Invest. 91: 443-447.
5. Boerwinkle, E., C. C. Leffert, J. Lin, C. Lackner, G. Chiesa, and H. H. Hobbs. 1992. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J. Clin. Invest. 90: 52-60.
6. Koschinsky, M. L., and S. M. Marcovina. 2004. Structure-function relationships in apolipoprotein(a): insights into lipoprotein(a) assembly and pathogenicity. Curr. Opin. Lipidol. 15: 167-174.
7. Kostner, K. M., M. Clodi, G. Bodlaj, B. Watschinger, W. Horl, K. Derfler, and K. Huber. 1998. Decreased urinary apolipoprotein(a) excretion in patients with impaired renal function. Eur. J. Clin. Invest. 28: 447-452.
8. Sechi, L. A., L. Zingaro, S. De Carli, G. Sechi, C. Catena, E. Falleti, E. Dell'Anna, and E. Bartoli. 1998. Increased serum lipoprotein(a) levels in patients with early renal failure. Ann. Intern. Med. 129: 457-461.
9. Kronenberg, F., E. Trenkwalder, A. Lingenhel, G. Friedrich, K. Lhotta, M. Schober, N. Moes, P. Konig, G. Utermann, and H. Dieplinger. 1997. Renovascular arteriovenous differences in Lp[a] plasma concentrations suggest removal of Lp[a] from the renal circulation. J. Lipid Res. 38: 1755-1763.
10. Wiklund, O., B. Angelin, S. O. Olofsson, M. Eriksson, G. Fager, L. Berglund, and G. Bondjers. 1990. Apolipoprotein(a) and ischaemic heart disease in familial hypercholesterolaemia. Lancet. 335: 1360-1363.
11. Floren, C. H., J. J. Albers, and E. L. Bierman. 1981. Uptake of Lp(a) lipoprotein by cultured fibroblasts. Biochem. Biophys. Res. Commun. 102: 636-639.
12. Krempler, F., G. M. Kostner, A. Roscher, F. Haslauer, K. Bolzano, and F. Sandhofer. 1983. Studies on the role of specific cell surface receptors in the removal of lipoprotein (a) in man. J. Clin. Invest. 71: 1431-1441.
13. Havekes, L., B. J. Vermeer, T. Brugman, and J. Emeis. 1981. Binding of Lp(a) to the low density lipoprotein receptor of human fibroblasts. FEBS Lett. 132: 169-173.
14. Mbewu, A. D., D. Bhatnagar, P. N. Durrington, L. Hunt, M. Ishola, S. Arrol, M. Mackness, P. Lockley, and J. P. Miller. 1991. Serum lipoprotein(a) in patients heterozygous for familial hypercholesterolemia, their relatives, and unrelated control populations. Arterioscler. Thromb. 11: 940-946.
15. Utermann, G., F. Hoppichler, H. Dieplinger, M. Seed, G. Thompson, and E. Boerwinkle. 1989. Defects in the low density lipoprotein receptor gene affect lipoprotein (a) levels: multiplicative interaction of two gene loci associated with premature atherosclerosis. Proc. Natl. Acad. Sci. USA. 86: 4171-4174.
16. Niemeier, A., T. Willnow, H. Dieplinger, C. Jacobsen, N. Meyer, J. Hilpert, and U. Beisiegel. 1999. Identification of megalin/gp330 as a receptor for lipoprotein(a) in vitro. Arterioscler. Thromb. Vasc. Biol. 19: 552-561.
17. Marz, W., A. Beckmann, H. Scharnagl, R. Siekmeier, U. Mondorf, I. Held, W. Schneider, K. T. Preissner, L. K. Curtiss, W. Gross, et al. 1993. Heterogeneous lipoprotein (a) size isoforms differ by their interaction with the low density lipoprotein receptor and the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor. FEBS Lett. 325: 271-275.
18. Argraves, K. M., K. F. Kozarsky, J. T. Fallon, P. C. Harpel, and D. K. Strickland. 1997. The atherogenic lipoprotein Lp(a) is internalized and degraded in a process mediated by the VLDL receptor. J. Clin. Invest. 100: 2170-2181.
19. Mahley, R. W., and Z. S. Ji. 1999. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. J. Lipid Res. 40: 1-16.
20. van Barlingen, H. H., H. A. Kleinveld, D. W. Erkelens, and T. W. de Bruin. 1997. Lipoprotein lipase-enhanced binding of lipoprotein(a) [Lp(a)] to heparan sulfate is improved by apolipoprotein E (apoE) saturation: secretion-capture process of apoE is a possible route for the catabolism of Lp(a). Metabolism. 46: 650-655.
21. Rader, D. J., W. A. Mann, W. Cain, H. G. Kraft, D. Usher, L. A. Zech, J. M. Hoeg, J. Davignon, P. Lupien, M. Grossman, et al. 1995. The low density lipoprotein receptor is not required for normal catabolism of Lp(a) in humans. J. Clin. Invest. 95: 1403-1408.
22. Edelstein, C., M. Mandala, D. Pfaffinger, and A. M. Scanu. 1995. Determinants of lipoprotein(a) assembly: a study of wild-type and mutant apolipoprotein(a) phenotypes isolated from human and rhesus monkey lipoprotein(a) under mild reductive conditions. Biochemistry. 34: 16483-16492.
23. Pittman, R. C., and C. A. Taylor, Jr. 1986. Methods for assessment of tissue sites of lipoprotein degradation. Methods Enzymol. 129: 612-628.
24. Brown, R. P., M. D. Delp, S. L. Lindstedt, L. R. Rhomberg, and R. P. Beliles. 1997. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health. 13: 407-484.
25. Hrzenjak, A., S. Frank, X. Wo, Y. Zhou, T. Van Berkel, and G. M. Kostner. 2003. Galactose-specific asialoglycoprotein receptor is involved in lipoprotein (a) catabolism. Biochem. J. 376: 765-771.
26. Lawn, R. M., N. W. Boonmark, K. Schwartz, G. E. Lindahl, D. P. Wade, C. D. Byrne, K. J. Fong, K. Meer, and L. Patthy. 1995. The recurring evolution of lipoprotein(a). Insights from cloning of hedgehog apolipoprotein(a). J. Biol. Chem. 270: 24004-24009.
27. Callow, M. J., L. J. Stoltzfus, R. M. Lawn, and E. M. Rubin. 1994. Expression of human apolipoprotein B and assembly of lipoprotein(a) in transgenic mice. Proc. Natl. Acad. Sci. USA. 91: 2130-2134.
28. Cheesman, E. J., R. J. Sharp, C. H. Zlot, C. Y. Liu, S. Taylor, S. M. Marcovina, S. G. Young, and S. P. McCormick. 2000. An analysis of the interaction between mouse apolipoprotein B100 and apolipoprotein(a). J. Biol. Chem. 275: 28195-28200.
29. Chiesa, G., H. H. Hobbs, M. L. Koschinsky, R. M. Lawn, S. D. Maika, and R. E. Hammer. 1992. Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a). J. Biol. Chem. 267: 24369-24374.
30. Linton, M. F., R. V. Farese, Jr., G. Chiesa, D. S. Grass, P. Chin, R. E. Hammer, H. H. Hobbs, and S. G. Young. 1993. Transgenic mice expressing high plasma concentrations of human apolipoprotein B100 and lipoprotein(a). J. Clin. Invest. 92: 3029-3037.
31. Callow, M. J., J. Verstuyft, R. Tangirala, W. Palinski, and E. M. Rubin. 1995. Atherogenesis in transgenic mice with human apolipoprotein B and lipoprotein (a). J. Clin. Invest. 96: 1639-1646.
32. Lawn, R. M., D. P. Wade, R. E. Hammer, G. Chiesa, J. G. Verstuyft, and E. M. Rubin. 1992. Atherogenesis in transgenic mice expressing human apolipoprotein(a). Nature. 360: 670-672.
33. Sanan, D. A., D. L. Newland, R. Tao, S. Marcovina, J. Wang, V. Mooser, R. E. Hammer, and H. H. Hobbs. 1998. Low density lipoprotein receptor-negative mice expressing human apolipoprotein B-100 develop complex atherosclerotic lesions on a chow diet: no accentuation by apolipoprotein(a). Proc. Natl. Acad. Sci. USA. 95:4544-4549.
34. Gabelli, C., R. E. Gregg, L. A. Zech, E. Manzato, and H. B. Brewer, Jr. 1986. Abnormal low density lipoprotein metabolism in apolipoprotein E deficiency. J. Lipid Res. 27: 326-333.
35. 3H]cholesteryl linoleyl ether-labeled human Lp(a) in different rat organs. Biochim. Biophys. Acta. 963: 534-540.
36. Kronenberg, F., K. Lhotta, P. Konig, R. Margreiter, H. Dieplinger, and G. Utermann. 2003. Apolipoprotein(a) isoform-specific changes of lipoprotein(a) after kidney transplantation. Eur. J. Hum. Genet. 11: 693-699.
37. Kronenberg, F., A. Lingenhel, K. Lhotta, B. Rantner, M. F. Kronenberg, P. Konig, J. Thiery, M. Koch, A. von Eckardstein, and H. Dieplinger. 2004. The apolipoprotein(a) size polymorphism is associated with nephrotic syndrome. Kidney Int. 65: 606-612.
38. Mooser, V., M. C. Seabra, M. Abedin, K. T. Landschulz, S. Marcovina, and H. H. Hobbs. 1996. Apolipoprotein(a) kringle 4-containing fragments in human urine. Relationship to plasma levels of lipoprotein(a). J. Clin. Invest. 97: 858-864.
39. Oida, K., H. Takai, H. Maeda, S. Takahashi, A. Shimada, J. Suzuki, T. Tamai, T. Nakai, and S. Miyabo. 1992. Apolipoprotein(a) is present in urine and its excretion is decreased in patients with renal failure. Clin. Chem. 38: 2244-2248.
40. Doucet, C., V. Mooser, S. Gonbert, F. Raymond, J. Chapman, C. Jacobs, and J. Thillet. 2000. Lipoprotein(a) in the nephrotic syndrome: molecular analysis of lipoprotein(a) and apolipoprotein(a) fragments in plasma and urine. J. Am. Soc. Nephrol. 11: 507-513.
41. Mooser, V., S. M. Marcovina, A. L. White, and H. H. Hobbs. 1996. Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine. J. Clin. Invest. 98: 2414-2424.
42. Armstrong, V. W., B. Harrach, H. Robenek, M. Helmhold, A. K. Walli, and D. Seidel. 1990. Heterogeneity of human lipoprotein Lp[a]: cytochemical and biochemical studies on the interaction of two Lp[a] species with the LDL receptor. J. Lipid Res. 31: 429-441.
43. Maartmann-Moe, K., and K. Berg. 1981. Lp(a) lipoprotein enters cultured fibroblasts independently of the plasma membrane low density lipoprotein receptor. Clin. Genet. 20: 352-362.
44. Reblin, T., A. Niemeier, N. Meyer, T. E. Willnow, F. Kronenberg, H. Dieplinger, H. Greten, and U. Beisiegel. 1997. Cellular uptake of lipoprotein[a] by mouse embryonic fibroblasts via the LDL receptor and the LDL receptor-related protein. J. Lipid Res. 38: 2103-2110.
45. Perombelon, Y. F., J. J. Gallagher, N. B. Myant, A. K. Soutar, and B. L. Knight. 1992. Lipoprotein(a) in subjects with familial defective apolipoprotein B100. Atherosclerosis. 92: 203-212.
46. Hofmann, S. L., D. L. Eaton, M. S. Brown, W. J. McConathy, J. L. Goldstein, and R. E. Hammer. 1990. Overexpression of human low density lipoprotein receptors leads to accelerated catabolism of Lp(a) lipoprotein in transgenic mice. J. Clin. Invest. 85: 1542-1547.
47. Ramharack, R., T. M. Bocan, M. J. Imperiale, and M. A. Spahr. 1999. Recombinant adenovirus vector mediated expression of lipoprotein (a) [Lp(a)] in rabbit plasma. Biochim. Biophys. Acta. 1438: 322-328.
48. Fan, J., M. Challah, H. Shimoyamada, M. Shiomi, S. Marcovina, and T. Watanabe. 2000. Defects of the LDL receptor in WHHL transgenic rabbits lead to a marked accumulation of plasma lipoprotein [a]. J. Lipid Res. 41: 1004-1012.
49. Woollett, L. A., Y. Osono, J. Herz, and J. M. Dietschy. 1995. Apolipoprotein E competitively inhibits receptor-dependent low density lipoprotein uptake by the liver but has no effect on cholesterol absorption or synthesis in the mouse. Proc. Natl. Acad. Sci. USA. 92: 12500-12504.
50. Tiebel, O., K. Oka, K. Robinson, M. Sullivan, J. Martinez, M. Nakamuta, K. Ishimura-Oka, and L. Chan. 1999. Mouse very low-density lipoprotein receptor (VLDLR): gene structure, tissue-specific expression and dietary and developmental regulation. Atherosclerosis. 145: 239-251.
51. Zheng, G., D. R. Bachinsky, I. Stamenkovic, D. K. Strickland, D. Brown, G. Andres, and R. T. McCluskey. 1994. Organ distribution in rats of two members of the low-density lipoprotein receptor gene family, gp330 and LRP/alpa 2MR, and the receptor-associated protein (RAP). J. Histochem. Cytochem. 42: 531-542.
52. Bottalico, L. A., G. A. Keesler, G. M. Fless, and I. Tabas. 1993. Cholesterol loading of macrophages leads to marked enhancement of native lipoprotein(a) and apoprotein(a) internalization and degradation. J. Biol. Chem. 268: 8569-8573.
53. Fless, G. M., M. E. ZumMallen, and A. M. Scanu. 1986. Physicochemical properties of apolipoprotein(a) and lipoprotein(a) derived from the dissociation of human plasma lipoprotein (a). J. Biol. Chem. 261: 8712-8718.
54. Spiess, M. 1990. The asialoglycoprotein receptor: a model for endocytic transport receptors. Biochemistry. 29: 10009-10018.
55. Wu, J., P. Liu, J. L. Zhu, S. Maddukuri, and M. A. Zern. 1998. Increased liver uptake of liposomes and improved targeting efficacy by labeling with asialofetuin in rodents. Hepatology. 27: 772-778.
56. Keesler, G. A., B. R. Gabel, C. M. Devlin, M. L. Koschinsky, and I. Tabas. 1996. The binding activity of the macrophage lipoprotein(a)/ apolipoprotein(a) receptor is induced by cholesterol via a post-translational mechanism and recognizes distinct kringle domains on apolipoprotein(a). J. Biol. Chem. 271: 32096-32104.
57. Devlin, C. M., S. J. Lee, G. Kuriakose, C. Spencer, L. Becker, I. Grosskopf, C. Ko, L. S. Huang, M. L. Koschinsky, A. D. Cooper, et al. 2005. An apolipoprotein(a) peptide delays chylomicron remnant clearance and increases plasma remnant lipoproteins and atherosclerosis in vivo. Arterioscler. Thromb. Vasc. Biol. 25: 1704-1710.